Partnering for Success in Thailand Pharmacovigilance
DDReg provides pharmacovigilance services in Thailand for pharmaceutical, biologics, and vaccine marketing authorisation holders (MAHs). Our team manages all post-marketing safety reporting obligations to the Thai FDA's Health Product Vigilance Center (HPVC), operates local pharmacovigilance systems for foreign MAHs without Thai representation, coordinates NC-status new drug intensive monitoring, and delivers pharmacovigilance outsourcing Thailand mandates across the full product lifecycle.
Thailand's Pharmacovigilance Regulatory Framework
The Thai Food and Drug Administration (Thai FDA), operating under the Ministry of Public Health, holds regulatory authority over post-marketing drug safety surveillance in Thailand. Within the Thai FDA, the Health Product Vigilance Center (HPVC) administers the national adverse drug reaction (ADR) reporting system - Thailand's Vigibase and receives all MAH safety submissions. Thailand joined the WHO International Drug Monitoring Programme in 1984 and the national PV system expanded from drug-focused vigilance (begun in 1983) to a full health product vigilance system in 2008, covering medicines, biologics, vaccines, herbal medicines, and medical devices.
The Thai FDA's pharmacovigilance obligations for MAHs are established by the Drugs Act B.E. 2510 (1967) and its amendments, supplemented by the Thai FDA Guidance for Marketing Authorization Holders on Post-Marketing Safety Reporting (updated in cooperation with PReMA, TPMA, and RAPAT). The scope of reporting covers spontaneous ADRs, solicited post-marketing study data, literature-identified cases, and foreign regulatory authority safety information. Lack of effect is classified as an adverse event under the Thai FDA framework, an important distinction from many other national systems.
The HPVC receives reports from healthcare professionals and consumers directly through the AE Online Reporting system (available at hpvcth.fda.moph.go.th), by fax, by email, or by post. CIOMS forms are accepted alongside the Thai FDA adverse event reporting form. The Thai Vigibase contains ADR reports from all 77 provinces; HPVC applies the Reporting Odds Ratio (ROR) method for quantitative signal generation. Signal confirmation triggers risk management measures and regulatory communication to MAHs.
Thai FDA Pharmacovigilance Obligations - MAH Summary
| Obligation | Scope | Deadline / Frequency |
|---|---|---|
| Expedited ADR report: fatal or life-threatening | Serious unexpected ADRs; domestic and foreign occurrences | Immediate (as soon as possible); within 7 calendar days for SUSARs in clinical trials |
| Expedited ADR report: serious non-fatal/non-life-threatening | Serious unexpected ADRs not meeting urgent criteria | Within 15 days of first knowledge |
| NC-status intensive monitoring reports | New drugs with 'NC' registration number and triangle label; risk level 1–4 assigned at approval | Per risk-level reporting schedule for at least 2 years post-marketing |
| PBRER / PSUR | All MAH products upon Thai FDA request | On Thai FDA request; not a mandatory proactive submission unless requested |
| Risk Management Plan (RMP) | Thai FDA-designated products upon request | On Thai FDA request; not a mandatory proactive submission unless requested |
| Other safety information | Foreign regulatory authority actions, study safety signals that affect risk management | As soon as possible to HPVC |
| Literature monitoring | Published cases identifiable as MAH product; all therapeutic areas covered by MAH | Ongoing; reportable cases submitted per expedited timeline |
Pharmacovigilance Outsourcing Thailand - DDReg Services
DDReg provides pharmacovigilance outsourcing Thailand mandates across four service areas: local PV system operation, adverse event reporting, safety documentation, and signal and risk management.
-
Local Pharmacovigilance System Operation
-
Adverse Event Reporting to HPVC
-
Drug Safety Services Thailand - Safety Documentation
-
Pharmacovigilance Consultant Thailand - Strategic and Advisory Services
NC-Status New Drug Monitoring - A Thailand-Specific Requirement
New drugs, new generic drugs, and new biological products approved by the Thai FDA receive a registration number ending in 'NC' and carry a triangle label marked 'must monitor'. These products are subject to intensive post-marketing safety monitoring for a minimum of two years after approval and market entry. Distribution is restricted to hospitals and clinics; certain high-risk products are further restricted to hospitals only and labelled 'for hospital use only'.
The Thai FDA assigns each NC-status product a risk level at registration, from level 1 (highest risk, most intensive monitoring) through level 4. The risk level determines the reporting schedule the frequency and format of safety reports submitted to HPVC during the monitoring period. If safety data accumulated during the NC period demonstrates an adequate safety profile, the Thai FDA may grant unconditional approval: the 'NC' designation is removed, the triangle label is replaced, and distribution may extend beyond hospitals to drug stores if the product's prescription classification permits.
DDReg manages the complete NC-status monitoring programme from risk level determination at registration through intensive monitoring plan design, periodic HPVC report submission, and end-of-monitoring unconditional approval application. Companies without established Thai pharmacovigilance operations regularly outsource this programme to DDReg to ensure HPVC compliance throughout the two-year minimum monitoring period.
Thai FDA Adverse Event Reporting Timelines
| Event Type | Timeline | Submission Route |
|---|---|---|
| Fatal or life-threatening SADR (post-marketing) | Immediately (as soon as possible) | AE Online system, fax, email, or post to HPVC |
| Serious unexpected non-fatal SADR (post-marketing) | Within 15 days of first knowledge | AE Online system, fax, email, or post to HPVC |
| SUSAR in clinical trial: fatal/life-threatening | Within 7 calendar days | HPVC SAE form or CIOMS form; fax, email, or mail |
| SUSAR in clinical trial:non-fatal/non-life-threatening | Within 15 calendar days | HPVC SAE form or CIOMS form; fax, email, or mail |
| Foreign safety information affecting risk management | As soon as possible | HPVC notification; form or letter |
| NC-status intensive monitoring reports | Per risk-level schedule (level 1–4) | HPVC per approved monitoring plan |
| PBRER / PSUR | On Thai FDA HPVC request | Submitted to HPVC per request timeline |
| Clinical trial annual safety report | Within 3 months of 1-year anniversary | Thai FDA Medicines Regulation Division |
| Clinical trial end-of-study safety report | Within 6 months of study completion | Thai FDA Medicines Regulation Division |
| Medical device adverse event: public health threat | Immediate or within 48 hours | HPVC Medical Device Problem Reporting System |
| Medical device adverse event: death or life-threatening | Within 10 days | HPVC Medical Device Problem Reporting System |
| Medical device adverse event: serious harm risk on recurrence | Within 30 days | HPVC Medical Device Problem Reporting System |
Note: Follow-up reports must clearly reference the original HPVC report number. Lack of effect is classified as a reportable adverse event under Thai FDA guidance. HPVC accepts Thai FDA reporting form or CIOMS form.
Pharmacovigilance Company in Thailand - DDReg's Expertise
DDReg's pharmacovigilance consultants understand the Thai FDA HPVC reporting infrastructure: the AE Online system, the CIOMS-based Thai FDA adverse event form, fax and email submission channels, HPVC reference number management for follow-up reports, and the Thai Vigibase signal generation methods. This operational knowledge prevents procedural reporting errors that can generate Thai FDA queries and, for NC-status products, potentially delay the removal of monitoring restrictions.
The NC-status intensive monitoring programme is a Thailand-specific obligation with no direct equivalent in EU or US systems. DDReg manages the full programme, risk level determination at registration, HPVC monitoring plan compliance, periodic report submissions on the risk-level schedule, hospital distribution coordination, and end-of-monitoring unconditional approval application. This end-to-end management is the most common pharmacovigilance outsourcing Thailand engagement for newly registered innovative and generic products.
Thailand's framework does not mandate proactive PBRER/PSUR or RMP submission, these documents are required only on Thai FDA HPVC request. When HPVC requests a PBRER or RMP, the response window is defined by HPVC. DDReg prepares PBRER and RMP documents to ICH E2C(R2) and ICH E2E standards respectively, adapts the global document to Thai FDA expectations, and manages HPVC submission within the stipulated timeline.
Thai healthcare professionals and consumers report ADRs in Thai. HPVC communications, signal queries, and pharmacovigilance correspondence from the Thai FDA arrive in Thai. DDReg processes Thai-language incoming safety reports, translates HPVC queries for MAH response, and prepares Thai-language safety communications for healthcare professional distribution including Direct Healthcare Professional Communications (DHPCs) where HPVC requires them.
Pharmacovigilance signals and HPVC safety queries frequently require regulatory action labelling changes, distribution restriction modifications, or variation submissions to the Thai FDA registration division. DDReg's combined regulatory affairs and pharmacovigilance capability manages the full response: safety assessment, regulatory strategy, variation dossier preparation, Thai FDA submission, and HPVC notification without handoffs between separate service providers.
Global Reach Explorer
Find Your Solution
Our Pharmacovigilance (PV) Services Expertise
ICSR Case Processing and Submission
Our advanced Individual Case Safety Report (ICSR) Pharmacovigilance Services are dedicated to ensuring patient safety through precise case handling....
Literature Monitoring
DDReg’s Literature Monitoring Services offer advanced pharmacovigilance literature screening for drug safety. We help Marketing...
Risk Management
Our expert risk management solutions ensure patient safety by proactively addressing potential hazards in pharmaceutical...
Audit and Compliance
Our specialized services ensure that pharmacovigilance systems across the drug development pipeline meet strict regulatory...
Pharmacovigilance Signal Management Services
DDReg’s specialized pharmacovigilance services ensure that potential adverse events are identified and addressed promptly...
QPPV Services
DDReg’s expert team provides comprehensive QPPV services designed to strengthen your pharmacovigilance system. We ensure that...
